Patents by Inventor Anthony Coyle

Anthony Coyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING A TN3 SCAFFOLD AND METHODS OF USING THE SAME
    Publication number: 20250257120
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: January 16, 2025
    Publication date: August 14, 2025
    Applicant: Viela Bio, Inc.
    Inventors: Anthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David Kenneth SPENCER
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20250101116
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: February 27, 2023
    Publication date: March 27, 2025
    Inventors: ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
  • HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE
    Publication number: 20240417460
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic anti bodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: January 17, 2024
    Publication date: December 19, 2024
    Inventors: Melissa DAMSCHRODER, Peter KIENER, Herren WU, William DALL'ACQUA, Ronald HERBST, Anthony COYLE
  • COMPOSITIONS COMPRISING A TN3 SCAFFOLD AND METHODS OF USING THE SAME
    Publication number: 20230242619
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: November 1, 2022
    Publication date: August 3, 2023
    Inventors: Anthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David Kenneth SPENCER
  • Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomer
    Patent number: 11555062
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 17, 2023
    Assignee: Viela Bio, Inc.
    Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • NUCLEIC ACIDS ENCODING A TN3 SCAFFOLD COMPRISING A CD40L-SPECIFIC MONOMER SUBUNIT
    Publication number: 20220089688
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: July 28, 2021
    Publication date: March 24, 2022
    Applicant: Viela Bio, Inc.
    Inventors: Anthony COYLE, Manuel BACA, Thomas THISTED, Stacey DRABIC, Luba GRINBERG, Shabazz NOVARRA, Vaheh OGANESYAN, Ronald HERBST, David SPENCER
  • Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunit
    Patent number: 11104720
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 31, 2021
    Assignee: VIELA BIO, INC.
    Inventors: Anthony Coyle, Manual Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE
    Publication number: 20210061906
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: May 26, 2020
    Publication date: March 4, 2021
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20200172625
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 4, 2020
    Inventors: ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20200055944
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: July 15, 2019
    Publication date: February 20, 2020
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • Anti-IFNAR1 antibodies with reduced Fc ligand affinity
    Patent number: 10301390
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • CD40L-Specific TN3-Derived Scaffolds and Methods Of Use Thereof
    Publication number: 20180312572
    Abstract: The present invention provides Tenascin-3 Fnlll domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Application
    Filed: May 31, 2018
    Publication date: November 1, 2018
    Inventors: Anthony Coyle, Manual Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE
    Publication number: 20180273621
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: January 5, 2018
    Publication date: September 27, 2018
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20180244791
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: May 4, 2018
    Publication date: August 30, 2018
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • CD40L-specific TN3-derived scaffolds and methods of use thereof
    Patent number: 10000553
    Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
    Type: Grant
    Filed: October 10, 2012
    Date of Patent: June 19, 2018
    Assignee: Viela Bio, Inc.
    Inventors: Anthony Coyle, Manuel Baca, Thomas Thisted, Stacey Drabic, Luba Grinberg, Shabazz Novarra, Vaheh Oganesyan, Ronald Herbst, David Kenneth Spencer
  • Anti-IFNAR1 antibodies with reduced Fc ligand affinity
    Patent number: 9988459
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: June 5, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Anthony Coyle, Peter Kiener, Herren Wu, Ricardo Cibotti
  • ANTI-IFNAR1 ANTIBODIES WITH REDUCED FC LIGAND AFFINITY
    Publication number: 20180118839
    Abstract: The invention provides anti-IFNAR1 antibodies with reduced affinity for Fc receptors and/or ligands and methods of making and using such antibodies.
    Type: Application
    Filed: September 21, 2017
    Publication date: May 3, 2018
    Inventors: ANTHONY COYLE, PETER KIENER, HERREN WU, RICARDO CIBOTTI
  • Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
    Patent number: 9896505
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: February 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF
    Publication number: 20170121771
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: October 11, 2016
    Publication date: May 4, 2017
    Applicant: MEDIMMUNE, LLC
    Inventors: YIHONG YAO, BAHIJA JALLAL, RICARDO CIBOTTI, ANTHONY COYLE, PETER KIENER
  • HUMAN ANTI IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-LIFE AND THEIR USE IN TREATMENT OF ONCOLOGY, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
    Publication number: 20170101468
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: December 2, 2016
    Publication date: April 13, 2017
    Inventors: Michael Bowen, Herren Wu, William Dall'Acqua, Peter Kiener, Bahija Jallal, Anthony Coyle